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Background:NT-proBNP concentrations reflect a wide range of structural and functional cardiac parameters. We recently showed that heart 
failure (HF) therapy with a goal to lower NT-proBNP concentrations <1000 pg/mL reduced cardiovascular event rates in patients with left ventricular 
systolic dysfunction. Mechanistic explanations for such improved outcomes remain unknown.
Methods:  In a prospective, randomized study over 10 months of follow-up, 151 patients received either standard-of-care (SOC) management or 
treatment guided by NT-proBNP. Complete baseline to follow-up transthoracic echocardiogram (TTE) data were available in 116 (SOC, N=56; NT-
proBNP, N=60) and were analyzed as a function of 
treatment allocation.
Results:  NT-proBNP concentrations did not 
change in the SOC arm (baseline = 1776 vs. 
follow-up = 1865 pg/mL; P=.85), but fell in the 
NT-proBNP arm (2104 vs. 1094 pg/mL; P =.03). 
Compared to SOC, trends towards larger` blocker 
dose increases (+38% vs +49%; P=.09), as well as 
significantly more increase in aldosterone blockers 
(3% vs 22%; P =.01) were present in the NT-proBNP 
arm. Improvement in numerous TTE parameters was 
significantly greater in patients in the NT-proBNP 
arm (Table).
Conclusion:  Compared to SOC HF therapy, 
cardiac structure and function improved significantly 
more in HF patients treated with an NT-proBNP-
guided strategy. This provides a mechanistic insight 
into the clinical improvement seen with natriuretic-
peptide guided HF therapy.
Change in echocardiographic parameters in standard of care and natriuretic guided therapy
Parameter
SOC(N=56)
Median
[Interquartile range]
NT-proBNP (N=60)
Median
[Interquartile range]
P (NT-proBNP vs. SOC)
LV ejection fraction (%)
-Baseline
-Follow-up
-Percent change
30 [22-36]
34 [25-42]
8% [-16-58%]
25 [20-35]
33 [24-40]
18% [-4-45%]
.09
.67
.01
LV end-diastolic volume (mL/m2)
-Baseline
-Follow up
-Percent change
77 [60-90]
75 [58-87]
-3% [-8-14%]
85 [68-95]
78 [61-88]
-9% [-15-10%]
.08
.87
.008
LV end-systolic volume (mL/m2)
-Baseline
-Follow up
-Percent change
56 [40-69]
49 [38-55]
-7% [-14-10%]
65 [43-78]
49 [36-59]
-16% [-22-9%]
.11
.86
<.001
E/E’
-Baseline
-Follow up
-Percent change
12 [9-16]
12 [9-17]
-1% [-20-12%]
10 [7-15]
10 [7-13]
-13%[-31-26%]
.76
.39
.03
E/E’ <15
-Baseline
-Follow up
-Percent change
36%
34%
5%
25%
19%
24%
.05
<.001
<.001
RV fractional area change (%)
-Baseline
-Follow up
-Percent change
33 [27-42]
31 [17-39]
-11%[-37-15%]
33 [25-41]
40 [26-45]
5% [-19-40%]
.34
.008
<.001
RV ejection fraction (%)
-Baseline
-Follow up
-Percent change
47 [38-55]
47 [40-59]
0% [-13-28%]
45 [36-57]
53 [38-63]
7% [-9-32%]
.98
.10
.04
Estimated RV systolic pressure (mmHg)
-Baseline
-Follow up
-Percent change
43 [37-54]
37 [32-46]
-6% [-31-16%]
41 [35-49]
35 [32-43]
-13% [-32-0%]
.77
.49
.01
